Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Previous studies of the association between tenofovir and the coronavirus have yielded mixed results.
Two new studies come to different conclusions about the risk for severe illness and death.
The results point the way toward a universal coronavirus vaccine that could prevent future pandemics.
The immune response to the single-shot Johnson & Johnson vaccine remained robust against variants of SARS-CoV-2.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Previous studies of the association between tenofovir and COVID-19 outcomes in people with HIV have yielded mixed results.
The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats
The protein subunit vaccine provides 100% protection against moderate or severe disease, hospitalization and death.
Research suggests how to develop more broadly effective therapies and vaccines.
The Pfizer-BioNTech vaccine was 100% effective in a study of adolescents; trials for younger children are now underway.
Molnupiravir, first developed for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
People with immune deficiency may not respond as well to vaccines but could still gain some protection.
An immune balance protocol for pre- and post-vaccination
The CDC and FDA confirmed that the vaccine is safe, and said the recent pause should be lifted for all groups.
The federal government has paused administration of the vaccine while it investigates a rare blood clotting disorder.
Experts don’t yet know what causes long COVID or why some people have persistent symptoms while others recover in weeks or even days.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.